Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial.

@article{Kappos2016SafetyAE,
  title={Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial.},
  author={Ludwig Kappos and Douglas L. Arnold and Amit Bar-Or and John Camm and Tobias J Derfuss and Bernd C. Kieseier and Till Sprenger and Kristin Greenough and Pingping Ni and Tomohiko Harada},
  journal={The Lancet. Neurology},
  year={2016},
  volume={15 11},
  pages={
          1148-59
        }
}
BACKGROUND Patients with multiple sclerosis, a chronic inflammatory demyelinating disease of the central nervous system with autoimmune pathogenesis, have shown partial response to a number of immunomodulating treatments, but the search for more effective, safe, and convenient therapeutic options continues. Amiselimod is an oral selective modulator of sphingosine 1-phosphate 1 (S1P1) receptor, which is being developed for the treatment of various autoimmune-mediated diseases. We assessed the… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 21 times over the past 90 days. VIEW TWEETS